Lin BioScience, Inc. (6696.TWO)

TWD 139.5

(4.1%)

Market Cap (In TWD)

10.96 Billion

Revenue (In TWD)

-

Net Income (In TWD)

-687.19 Million

Avg. Volume

212.56 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
70.0-180.5
PE
-
EPS
-
Beta Value
-0.239
ISIN
TW0006696008
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zhengqi Wang M.B.A., Ph.D.
Employee Count
-
Website
https://www.linbioscience.com
Ipo Date
2018-10-08
Details
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.